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Myotonic dystrophies (DM) are repeat expansion diseases in
which expanded CTG (DM1) and CCTG (DM2) repeats cause
the disease. Mutant transcripts containing CUG/CCUG repeats
are retained in muscle nuclei producing ribonuclear inclu-
sions, which can bind specific RNA-binding proteins, leading
to a reduction in their activity. The sequestration of muscle-
blind-like proteins (MBNLs), a family of alternative splicing
factors, appears to be involved in splicing defects characteris-
tic of DM pathologies. To determine whether MBNL1 nuclear
sequestration is a feature of DM pathologies, we have exam-
ined the in vivo distribution of MBNL1 in muscle sections from
genetically confirmed DM1 (n=7) and DM2 (n=9) patients,
patients with other myotonic disorders (n=11) and from
patients with disorders caused by repeat expansions, but not
DM1/DM2 (n=3). The results of our immunofluorescence
study indicate that, among patients examined, MBNL1 nuclear
sequestration in protein foci is a molecular pathology marker
of DM1 and DM2 patients where ribonuclear inclusions of
transcripts with expanded CUG/CCUG repeats are also pres-
ent. These findings indicate that MBNLs might be important
targets for therapeutic interventions to correct some of the
specific features of DM pathology.
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M
yotonic dystrophies (DM) are dominantly
inherited multisystemic disorders with sim-
ilar clinical, histological and genetic fea-
tures. They belong to the category of diseases now
commonly know as unstable repeat expansion disor-
ders since they are caused by two different
microsatellite expansions. Myotonic dystrophy type
1 (DM1) is caused by a CTG trinucleotide expan-
sion in the 3’ untraslated region of the dystrophya
myotonica-protein kinase (DMPK) gene on chromo-
some 19 (Brook et al., 1992, Fu et al., 1992;
Mahadevan et al., 1992), whereas myotonic dystro-
phy type 2 (DM2) is caused by a CCTG tetranu-
cleotide expansion in intron 1 of the zinc finger pro-
tein 9 (ZNF9) gene on chromosome 3 (Ranum et
al., 1998; Liquori et al., 2001). A characteristic
disease feature is that transcripts from the mutant
allele cannot be exported to the cytoplasm but are
retained in muscle nuclei producing ribonuclear
inclusions that can be evidenced by in situ hybridiza-
tion (Taneja et al., 1995; Davis et al., 1997;
Liquori et al., 2001; Mankodi et al., 2001, 2003;
Cardani et al., 2004).
One proposed mechanism to explain the molecular
basis of DM pathogenesis is that nuclear accumula-
tion of mutant RNAs that contain expanded CUG or
CCUG repeats adversely affects nuclear functions.
An RNA gain of function mechanism via sequestra-
tion or aberrant activation of RNA-binding proteins,
is one of the mechanism proposed to explain how
ribonuclear inclusions might play a role in DM
pathogenesis. Several proteins have been suggested
to interact with CUG/CCUG repeats in in vitro or in
vivo experiments, including CELF proteins (CUG-
binding protein 1 (CUG-BP1) and elav-like RNA-
binding protein 3 (ETR3)), protein kinase R (PKR)
and muscleblind-like proteins (MBNLs) (Tim-
chenko et al., 1996;Tian et al., 2000; Miller et al.,
2000).
MBNLs were identified as a family of RNA-bind-
ing proteins by Miller et al., (2000).These proteins
are homologus of muscleblind in Drosophila
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melanogaster where it is involved in the terminal
differentiation of muscle (Artero et al., 1998) and
of photoreceptor cells in the eye (Begemann et al.,
1997). Three mammalian muscleblind genes have
been recognized although their function is not well
understood: MBNL1, MBNL2 and MBNL3 (Miller
et al., 2000; Fardaei et al., 2002). It has been
demonstrated that MBNLs interact with
CUG/CCUG repeats and with other repetitive
sequences in a yeast three-hybrid system and in in
vitro binding experiments (Kino et al., 2003,
2004). By using fluorescence in situ hybridization
(FISH), it has been reported that MBNLs, in con-
trast to CUG-BP and PKR, showed a clear colo-
calization with DM1 or DM2 ribonuclear inclusions
both in muscle tissue and cell cultures (Fardaei et
al., 2001, 2002; Mankodi et al., 2001, 2003).
These observations seem indicate that muscleblind
proteins are sequestered in CUG/CCUG containing
RNA foci and they cannot perform their normal
functions. An indication that sequestration of
MBNLs plays a central role in DM pathogenesis
comes from recent studies of Kanadia et al.,
(2003). These authors developed a muscleblind
knockout model of myotonic dystrophy in which
disruption of the mouse Mbnl1 gene leads to mus-
cle, eye and RNA-splicing abnormalities that are
characteristic of DM disease. More recently Ho et
al., (2004) demonstrated that these proteins are
splicing factors and compete with CUG-BP1 to
regulate alternative splicing of specific pre-mRNA
that are misregulated in DM pathogenesis. At least
5 of the 13 misregulated splicings observed in DM
pathologies are consistent with the loss of MBNL1
and/or gain of CUG-BP1 activity. Splicing alter-
ations that lead to aberrant expression of several
proteins, including chloride channel, insulin recep-
tor and cardiac troponin c, underlie the complex
multisystemic phenotype of DM disorders like
myotonia, insulin resistance and cardiac defects
(Gatchel et al., 2005; Day and Ranum, 2005).
In our study we have examined if MBNL1 deple-
tion, due to nuclear sequestration, is a characteris-
tic feature of DM pathologies where ribonuclear
inclusions are also present.Thus, we have compared
the in vivo MBNL1 distribution observed in muscle
biopsies from DM patients with that observed in
muscle biopsies from patients with other myotonic
disorders and in patients with other types of disor-
ders caused by repeat expansions similar to those of
DM pathologies. Spinobulbar muscular atrophy
(SBMA) and Huntington’s disease (HD) are neuro-
logical diseases caused by the expansions of CAG
repeat that lead to proteins with expanded polyglu-
tamine stretches. However, evidences suggest that,
as for DM pathologies, RNA with expanded repeat
are present in the nucleus and form RNA-protein
complexes with RNA-binding proteins that lead to
neuronal and muscle degeneration (Broude and
Cantor, 2003).
Materials and Methods
Tissue samples and patients 
Human muscle biopsies from biceps brachii mus-
cle were taken under sterile conditions and pre-
pared by snap-freezing in cooled isopentane. The
biopsies were used for this study after informed
consent from patients.
The clinical diagnosis of DM1 (n=7) and DM2
patients (n=9) was based upon the criteria set by
the International Consortium for Myotonic
Dystrophies (Moxley et al., 2002).The histological
diagnosis was performed on serial sections (10 µm)
of muscle biopsies from all of these patients
processed for routine histological or histochemical
stainings. A standard myofibrillar ATPase staining
protocol was used after preincubation at pH 4.3,
pH 4.6, and pH 9.4 or 10.4 (Dubowitz, 1985).
Antibodies against different myosin heavy chain
(MHC) isotypes were used for immunohistochemi-
cal identification of very small fast or slow fibers
according to Vihola et al., (2003).
The genetic confirmation of DM2 was performed
by repeat assay described by Bachinski et al.,
(2003). DM1 patients were genetically confirmed
by PCR or Southern blot on DNA lymphocytes.
Fluorescence in situ hybridization was performed
on frozen sections from DM1 or DM2 patients
using a (CAG)6CA or (CAGG)5 probe respectively,
as reported by Cardani et al., (2004).
A total of 8 patients with non-dystrophic myoton-
ic disorders (6 chloride channelopathies, 2 sodium
channelopathies), 3 non-DM1/DM2 patients, 1
patient affected by spinal and bulbar muscular
atrophy (SBMA) and 2 affected by Huntington’s
disease (HD) were also examined. Control muscle
biopsies were taken from healthy subjects (n=5).
MBNL1 immunofluorescence
Transverse muscle cryostat sections (5-6 µm)
were dried for 1 hour at room temperature and then
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fixed in 2% paraformaldehyde for 30 min. at 4°C.
Sections were washed five times in phosphate-
buffered saline (PBS) for 3 min. at room tempera-
ture and then preincubated with normal goat serum
(DAKO) at a dilution 1:20 in PBS containing 2%
bovine serum albumin (BSA) for 20 min. at room
temperature. The primary antibody, a polyclonal
rabbit anti-muscleblind1 (MBNL1; gift of Prof.
C.A. Thornton, University of Rochester, New York,
USA) was applied at a dilution of 1:1000 in
PBS+2% BSA overnight at 4°C. After washing in
PBS 3 times for 5 min., sections were incubated
with secondary antibody (Alexa488-labeled goat
anti rabbit; Molecular Probes) diluted 5 µg/µL in
PBS+2% BSA for 1 hour at room temperature.
Following incubation, sections were washed 3 times
with PBS and nuclei were stained with 165 nM 4,6
diamidino-2-phenylindole (DAPI). Sections were
then mounted with Gel Mount mounting medium
(Biomedia corp) and examined using a fluorescence
microscope.
FISH and immunofluorescence
FISH procedure, using RNA (CAG)6CA or
(CAGG)5 Texas red labelled probes (IDT,
Coralville, IA) on DM1 or DM2 muscle sections
respectively, was carried out as previously reported
by Cardani et al., (2004). Following the 1XSSC
post-hybridization wash without DAPI, the
immunofluorescence protocol was performed as
described above starting from the incubation with
normal goat serum.The interaction between ribonu-
clear inclusions and MBNL1 nuclear accumulation
was examined by analysis of images obtained at
confocal microscopy.
Results
We have used an anti-MBNL1 polyclonal anti-
body to examine the distribution of MBNL1 in sec-
tions of skeletal muscle from DM1 or DM2
patients, in patients with other myotonic disorders
and in patients with other types of repeat expan-
sions disorders. In skeletal muscle from healthy
patients, MBNL1 is localised primarily in the nucle-
us where is uniformly distributed. The same distri-
bution is observed in nuclei of skeletal muscles
from the 7 patients with chloride or sodium chan-
nelopathies, from the 3 non-DM1/DM2 patients
and from the patients affected by SBMA or HD
(Figure 1A-C). In these patients, the intensity of
immunofluorescence nuclear staining appears to be
equal to that observed in muscle nuclei of healthy
controls. In DM1 and DM2 patients, myonuclei
show intensely fluorescent MBNL1 foci that repre-
sent high concentration of the protein (Figure 1D,
E). Although MBNL1 nuclear sequestration,
MBNL1 is still expressed in the nucleoplasm both
in DM1 and DM2 myonuclei, but on the whole, the
immunofluorescence intensity of the nucleoplasm
seems to be lower in DM nuclei than in the nuclei
of all the other muscle sections examined. The
analysis of the number of MBNL1 foci per nucleus
reveals that the majority of DM1 myonuclei show 1
focus per nucleus and more rarely 2 foci per nucle-
us, whereas 1 to 3 foci per nucleus are found in
DM2 muscle sections. However, nuclei without pro-
tein foci are also present both in DM1 and DM2
muscle sections. Moreover, it should be noted that
MBNL1 foci appear to be larger in DM2 than in
DM1 nuclei. The nuclear MBNL1 accumulation
observed in DM1 and DM2 muscle nuclei is com-
pletely absent from the myonuclei of all the control
muscle sections examined.
FISH analysis, using (CAG)6CA or (CAGG)5
probe on DM1 and DM2 muscle sections respec-
tively, has confirmed that DM patients used in this
study showed nuclear accumulations of mutant
transcripts, with no foci observed in nuclei of mus-
cle sections from healthy patients. By using FISH
in combination with immunofluorescence, it
appears that focal accumulation of MBNL1 in DM
myonuclei co-localize precisely with the foci of
transcripts containing the CUG/CCUG expansions
(Figure 1F-H).
Discussion
Evidences suggest that in DM disease, ribonu-
clear inclusions are directly involved in pathogene-
sis through a gain-of-function mechanism that
involves protein sequestration. Among the different
proteins suggested to interact with CUG/CCUG
repeats, only muscleblind proteins show a clear
colocalization with RNA foci both in muscle tissue
and cell cultures (Fardaei et al., 2001, 2002;
Mankodi et al., 2001, 2003).
Our examination of MBNL1 expression in skele-
tal muscle sections show that nuclear sequestration
of this protein is a feature of DM pathology where
ribonuclear inclusions of transcripts with expanded
CUG/CCUG repeats are also present. So, the pres-
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Figure 1. A-C. Immunofluorescence analysis of MBNL1 distribution in human skeletal muscle tissue at fluorescence microscopy.
MBNL1 is localized primarily in the nucleus of muscle sections from patient with chloride channelopathy (A), from a non-DM1/DM2
patient (B) and from a patient affected by Huntington’s disease (C). Brown material present in (B) is autofluorescent lipofuscin.
Original magnification x600. D-H. Analysis of MBNL1 distribution at confocal microscopy in DM muscle sections. Foci of MBNL1 are
present in muscle nuclei of a DM1 patient (D) and of a DM2 patient (E). Ribonuclear inclusions (red) (F) and foci of MBNL1 (green)
(G) in DM2 muscle evidenced on the same muscle section using FISH in combination with immunofluorescence and acquired at two
different channels at confocal microscopy. Merged images show that MBNL1 co-localize with ribonuclear inclusions within DM2 mus-
cle nuclei (blue) (H).
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ence of nuclear foci of MBNL1 in DM muscle sec-
tions might be considered a molecular pathology
marker. Indeed no nuclear foci of the protein are
detectable either in non-DM patients with myoton-
ic disorders or in patients with neurological disor-
ders that are caused by unstable repeats similar to
those observed in DM patients. The size and num-
ber of MBNL1 foci appear to be greater in DM2
nuclei than in DM1, as expected since ZFN9
mRNA is more abundant than DMPK mRNA and
the size of expanded repeats is greater in DM2 than
in DM1 (Mankodi and Thornton, 2002) This could
indicate that MBNL1 is sequestred in ribonuclear
inclusions more in DM2 than in DM1, even if this
suggestion does not seem to be associated to a
reduction of protein expression in DM2 myonuclei
more than in DM1 myonuclei. The observation at
confocal microscope of muscle sections stained by
FISH in combination with immunofluorescence,
show a clear colocalization of ribonuclear inclu-
sions with MBNL1 foci. Moreover a reduction of
nucleoplasm immunofluorescence staining in the
most of DM myonuclei as compared to non-DM
muscle nuclei is also appreciable. Taken together
these observations indicate that MBNL1 is strong-
ly recruited to ribonuclear inclusions leading to a
protein depletion in the nucleoplasm. Similar
results are reported by Jiang et al., (2004) whose
quantitative analysis of MBNL1 fluorescence
intensity showed a lower mean immunofluorescence
intensity for MBNL1 in the nucleoplasm in DM1
neurons than in controls.
These results support the hypotesis that deple-
tion of MBNL1 due to sequestration of the protein
in ribonuclear inclusions, is involved in several
aspects of DM. Indeed, it has been shown that loss
of MBNL1 and/or gain of CUGBP1 activity lead
to at least 5 misregulated splicing events in DM
pathologies that result in aberrant proteins expres-
sion. Myotonia, cardiac defects and insulin resist-
ance could be caused by defective regulation of
alternative splicing for chloride channel 1, cardiac
troponin T and insulin receptor respectively
(Savkur et al., 2001, 2004; Philips et al., 1998,
Charlet et al., 2002; Mankodi et al., 2002;).
Alterations in the splicing of myotubularin-related
1 gene have been also described in muscle tissue or
cells from DM1 patients (Buj-Bello et al., 2002).
Moreover, splicing alterations of the RNA encoding
the microtubule-associated Tau protein could
underlie the several CNS alterations observed in
DM patients (Sergeant et al., 2001).
Nevertheless the whole range of aberrantly
spliced genes that are involved in DM pathology
need to be clarified as well as the protein content of
the ribonuclear inclusions besides MBNLs. On the
other hand, it is well known that several human dis-
orders are associated with splicing defects and sev-
eral researches are in progress to test molecular
therapies targeting alternative splicing. As alterna-
tive splicing factors, MBNLs might be important
targets for therapeutic interventions to correct
some of the specific features of DM disease.
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